Literature DB >> 16896187

Rapamycin at subimmunosuppressive levels inhibits mesangial cell proliferation and extracellular matrix production.

Helen R Lock1, Steven H Sacks, Michael G Robson.   

Abstract

In view of its proven antiproliferative effects, rapamycin offers potential in the treatment of mesangioproliferative disease. Previous data have shown an effect of rapamycin on mesangial cell proliferation at high doses and have not explored the mechanism of action. Therefore, we explored the effects and mechanism of action of low levels of rapamycin on mesangial cell proliferation. Primary cultures of mouse mesangial cells were grown in medium containing serum with differing concentrations of rapamycin. A rapamycin concentration of 0.1 ng/ml caused a decrease in cell number and DNA synthesis with no effect on apoptosis. Type IV collagen protein production was inhibited at 0.01 ng/ml rapamycin, although gene expression was unaffected. P70S6K phosphorylation was inhibited in parallel with the effects on cell number and DNA synthesis in a dose-dependent manner, but no effect was seen at 0.01 ng/ml rapamycin. These data show an effect on mesangial cell proliferation and p70S6 kinase phosphorylation of 0.1 ng/ml rapamycin and an effect on collagen IV production of 0.01 ng/ml rapamycin. We suggest that further in vivo studies should explore the potential for low-dose rapamycin in the treatment of mesangioproliferative glomerulonephritis.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 16896187     DOI: 10.1152/ajprenal.00128.2006

Source DB:  PubMed          Journal:  Am J Physiol Renal Physiol        ISSN: 1522-1466


  9 in total

1.  Genetic disruption of Npr1 depletes regulatory T cells and provokes high levels of proinflammatory cytokines and fibrosis in the kidneys of female mutant mice.

Authors:  Venkateswara Reddy Gogulamudi; Indra Mani; Umadevi Subramanian; Kailash N Pandey
Journal:  Am J Physiol Renal Physiol       Date:  2019-04-03

2.  Rapamycin ameliorates IgA nephropathy via cell cycle-dependent mechanisms.

Authors:  Jihua Tian; Yanhong Wang; Xinyan Liu; Xiaoshuang Zhou; Rongshan Li
Journal:  Exp Biol Med (Maywood)       Date:  2014-10-27

3.  Rapamycin ameliorates chronic intermittent hypoxia and sleep deprivation-induced renal damage via the mammalian target of rapamycin (mTOR)/NOD-like receptor protein 3 (NLRP3) signaling pathway.

Authors:  Wei Liu; Dong Zhao; Xiaofeng Wu; Fang Yue; Haizhen Yang; Ke Hu
Journal:  Bioengineered       Date:  2022-03       Impact factor: 3.269

4.  Differential effects of rapamycin in anti-GBM glomerulonephritis.

Authors:  Kathrin Hochegger; Gerhard L Jansky; Afschin Soleiman; Anna M Wolf; Andrea Tagwerker; Christoph Seger; Andrea Griesmacher; Gert Mayer; Alexander R Rosenkranz
Journal:  J Am Soc Nephrol       Date:  2008-05-14       Impact factor: 10.121

5.  Rapamycin ameliorates kidney fibrosis by inhibiting the activation of mTOR signaling in interstitial macrophages and myofibroblasts.

Authors:  Guochun Chen; Huihui Chen; Chang Wang; Youming Peng; Lin Sun; Hong Liu; Fuyou Liu
Journal:  PLoS One       Date:  2012-03-28       Impact factor: 3.240

6.  Is There a Role for Mammalian Target of Rapamycin Inhibition in Renal Failure due to Mesangioproliferative Nephrotic Syndrome?

Authors:  Hernán Trimarchi; Mariano Forrester; Fernando Lombi; Vanesa Pomeranz; Romina Iriarte; María Soledad Raña; Pablo Young
Journal:  Int J Nephrol       Date:  2012-05-21

7.  Rapamycin inhibits transforming growth factor β-induced peritoneal angiogenesis by blocking the secondary hypoxic response.

Authors:  Yoshimi Sekiguchi; Jing Zhang; Sarah Patterson; Limin Liu; Chieko Hamada; Yasuhiko Tomino; Peter J Margetts
Journal:  J Cell Mol Med       Date:  2012-08       Impact factor: 5.310

8.  Rapamycin inhibits transforming growth factor β1-induced fibrogenesis in primary human lung fibroblasts.

Authors:  Yu Gao; Xuefeng Xu; Ke Ding; Yan Liang; Dianhua Jiang; Huaping Dai
Journal:  Yonsei Med J       Date:  2013-03-01       Impact factor: 2.759

9.  The protective effect and mechanism of rapamycin in the rat model of IgA nephropathy.

Authors:  Ning Guo; Shengli Liu; Laurine M Bow; Xianquan Cui; Luwei Zhang; Shihao Xu; Sai Lu; Jun Tian
Journal:  Ren Fail       Date:  2019-11       Impact factor: 2.606

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.